Immutep Efti, for Recurrent/Metastatic Head & Neck Cancer, Fast-Tracked

 

• Fast Track designation opens the potential for expedited development and review with the US FDA
• Fast Track was granted based on the promising data package from Immutep, including from Immutep’s Phase II TACTI-002 trial (Keynote-798) in head and neck squamous cell carcinoma (HNSCC)
• Start-up preparations for Immutep’s new Phase IIb TACTI-003 trial in 1st line HNSCC are advancing well

https://www.globenewswire.com/news-release/2021/04/08/2206638/0/en/Immutep-Achieves-Fast-Track-Designation-From-US-FDA-For-Efti-A-Soluble-Lag-3-Protein-In-First-Line-Recurrent-Metastatic-Head-Neck-Cancer.html